Market Impact
Transforming Global CTO Treatment Landscape
The current global market for CTO PCI devices is estimated over USD 2.0 billion and projected to exceed USD 3.0 billion by 2030, with a CAGR of around 7%, as hospitals continue to invest in dedicated CTO programs and novel device solutions.
TigerHeart™ is uniquely positioned to address this gap by combining mechanical crossing power with OCT-guided intraluminal navigation, offering a safer and more efficient way to treat hard-to-cross lesions. This creates a dual opportunity — improving patient outcomes while capturing share in a growing and underpenetrated market segment.
Reimbursement and Economic Advantages
Established reimbursement pathways (CPT Codes) already exist for both coronary CTO interventions and intravascular imaging procedures. This allows hospitals to adopt Tigerheart™ within their current clinical and billing frameworks without additional structural changes.
By enhancing procedural precision and crossing efficiency, Tigerheart™ enables physicians to achieve better outcomes in complex lesions while potentially reducing the need for multiple devices or repeat interventions. This not only supports improved patient care but also helps hospitals optimize overall procedural economics and resource utilization. As value-based healthcare models continue to gain importance worldwide, TigerHeart™ is well-positioned to align with the dual goals of clinical excellence and economic sustainability.
Technology and Clinical Impact
By integrating real-time Optical Coherence Tomography (OCT) imaging with a low-profile, steerable catheter, Tigerheart™ empowers interventional cardiologists to cross even the most challenging lesions with confidence and precision.​​
Why Tigerheart™ Stands Out
-
Redefining coronary CTO intervention with disruptive technology.
-
Democratizing CTO cases by improving success rates and ease of use.
-
Favourable reimbursement for coronary CTO procedures and OCT diagnostics already exists.
-
Economic value through reduced procedure time, ancillary device use, and contrast consumption.
